Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

NCT ID: NCT00616421

Last Updated: 2016-02-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2907 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningococcal Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MenACWY-CRM (1 dose)

1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.

Group Type EXPERIMENTAL

MenACWY-CRM

Intervention Type BIOLOGICAL

1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly

Licensed polysaccharide vaccine

1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1

Group Type ACTIVE_COMPARATOR

Licensed meningococcal ACWY vaccine

Intervention Type BIOLOGICAL

1 injection of the licensed meningococcal ACWY was administered intramuscularly

MenACWY-CRM (2 doses)

2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.

Group Type EXPERIMENTAL

MenACWY-CRM

Intervention Type BIOLOGICAL

2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MenACWY-CRM

1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly

Intervention Type BIOLOGICAL

MenACWY-CRM

2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age

Intervention Type BIOLOGICAL

Licensed meningococcal ACWY vaccine

1 injection of the licensed meningococcal ACWY was administered intramuscularly

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Menveo Menveo Menactra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent
* who are available for all visits and telephone calls scheduled for the study
* who are up-to-date with age-appropriate routine childhood vaccinations

Exclusion Criteria

* whose parent or legal guardian is unwilling or unable to give written informed consent
* who had a previous or suspected disease caused by N. meningitidis;
* who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
* who have received any investigational agents or vaccines within 90 days prior to enrollment
* who have any serious acute, chronic or progressive disease
* who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome
* who have a history of anaphylaxis, serious vaccine reactions
* who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from
* who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
* who have Down's syndrome or other known cytogenic disorders
Minimum Eligible Age

2 Years

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Vaccines

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Vaccines and Diagnostics

Role: STUDY_DIRECTOR

Novartis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Investigational Reserach Program

Bentonville, Arkansas, United States

Site Status

Arkansas Pediatric Research Group

Little Rock, Arkansas, United States

Site Status

Premier Health Research Center

Downey, California, United States

Site Status

Kaiser Permanente - Fremont

Fremont, California, United States

Site Status

Kaiser Permanente - Fresno

Fresno, California, United States

Site Status

Kaiser Permanente - Hayward

Hayward, California, United States

Site Status

Kaiser Permanente - Oakland

Oakland, California, United States

Site Status

Kaiser Permanente - Pleasanton

Pleasanton, California, United States

Site Status

Kaiser Permanente - San Francisco

San Francisco, California, United States

Site Status

Kaiser Permanente - San Jose

San Jose, California, United States

Site Status

Kaiser Permanente - Aurora

Aurora, Colorado, United States

Site Status

1st Allergy & Clinical Research

Centennial, Colorado, United States

Site Status

Longmont Medical Research Network

Longmont, Colorado, United States

Site Status

1st Allergy & Clinical Research

Thornton, Colorado, United States

Site Status

Kaiser Permanente - Westminister

Westminister, Colorado, United States

Site Status

Kentucky Pediatric Research Center

Bardstown, Kentucky, United States

Site Status

Physicians to Children & Adolescents

Springfield, Kentucky, United States

Site Status

Benchmark Research

Metairie, Louisiana, United States

Site Status

St. Louis University School of Medicine

St Louis, Missouri, United States

Site Status

Meridian Clinical Research LLC

Omaha, Nebraska, United States

Site Status

Legacy Pediatrics

Rochester, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Durham Pediatrics

Durham, North Carolina, United States

Site Status

Regional Pediatric Associates PA

Durham, North Carolina, United States

Site Status

Odyssey Research

Fargo, North Dakota, United States

Site Status

Dr. Senders and Associates

Cleveland, Ohio, United States

Site Status

Calcagno Research & Development

Gresham, Oregon, United States

Site Status

Children's Health Care - West

Erie, Pennsylvania, United States

Site Status

University Of Pittsburgh Medical Center

Greenville, Pennsylvania, United States

Site Status

Family Healthcare Partners

Grove City, Pennsylvania, United States

Site Status

Pediatric Associates of Latrobe

Latrobe, Pennsylvania, United States

Site Status

Pediatric Alliance PC

Pittsburgh, Pennsylvania, United States

Site Status

Pediatric Alliance PC

Pittsburgh, Pennsylvania, United States

Site Status

South Hills Pediatrics

Pittsburgh, Pennsylvania, United States

Site Status

Pediatric Alliance PC

Pittsburgh, Pennsylvania, United States

Site Status

Primary Physicians Research Inc.

Pittsburgh, Pennsylvania, United States

Site Status

Primary Physicians Research Inc.

Pittsburgh, Pennsylvania, United States

Site Status

Laurel Pediatrics

Uniontown, Pennsylvania, United States

Site Status

Family Practice Medical Associates South

Upper Saint Clair, Pennsylvania, United States

Site Status

Children's Community Pediatrics

Wexford, Pennsylvania, United States

Site Status

Jackson Clinic Professional Association

Jackson, Tennessee, United States

Site Status

Benchmark Research Ft. Worth

Fort Worth, Texas, United States

Site Status

Benchmark Research San Angelo

San Angelo, Texas, United States

Site Status

Jean Brown Research

Clinton, Utah, United States

Site Status

Wee Care Pediatrics

Layton, Utah, United States

Site Status

Cottonwood Pediatrics

Murray, Utah, United States

Site Status

J. Lewis Research Inc.

Salt Lake City, Utah, United States

Site Status

J. Lewis Research Inc.

Salt Lake City, Utah, United States

Site Status

Jean Brown Research

Salt Lake City, Utah, United States

Site Status

Copperview Medical Center

South Jordan, Utah, United States

Site Status

Rockwood Clinic

Spokane, Washington, United States

Site Status

Rockwood Clinic North

Spokane, Washington, United States

Site Status

TASC Research Services Inc.

Surrey, British Columbia, Canada

Site Status

Manitoba Clinic

Winnipeg, Manitoba, Canada

Site Status

Clinical Trials Research Center

Halifax, Nova Scotia, Canada

Site Status

Colchester Regional Hospital

Truro, Nova Scotia, Canada

Site Status

Albion Finch Medical Centre

Etobicoke, Ontario, Canada

Site Status

Medicor Research Inc.

Greater Sudbury, Ontario, Canada

Site Status

Children's Hospital of Western Ontario

London, Ontario, Canada

Site Status

SKDS Research In.

Newmarket, Ontario, Canada

Site Status

Herridge Community Health Clinic

Ottawa, Ontario, Canada

Site Status

Sarnia Institute of Clinical Research

Sarnia, Ontario, Canada

Site Status

Resolve Research Solutions

Toronto, Ontario, Canada

Site Status

Resolve Research Solutions

Toronto, Ontario, Canada

Site Status

Queen Elizabeth Hospital

Charlottetown, Prince Edward Island, Canada

Site Status

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status

Commonwealth Medical Clinic

Mount Pearl, , Canada

Site Status

White Hills Medical Clinic

St. John's, , Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010 Nov 23;28(50):7865-72. doi: 10.1016/j.vaccine.2010.09.092. Epub 2010 Oct 29.

Reference Type RESULT
PMID: 20943209 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11278

Identifier Type: -

Identifier Source: secondary_id

V59P20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.